
A Royal College of Physicians investigation found that cancer patients at University Hospitals Coventry and Warwickshire NHS trust experienced significant harm from prolonged and inappropriate chemotherapy treatment administered over several years.
The report examined cases of 20 brain tumor patients previously treated by Prof Ian Brown, a clinical oncologist whose patients were reassigned following his retirement in 2023. Investigators determined that 15 patients received unsatisfactory care while five cases required improvement. A central finding involved patients receiving extended cycles of the chemotherapy drug temozolomide far exceeding standard treatment protocols, without clinical evidence supporting continued administration. Some patients continued treatment despite disease progression, when palliative care would have been more appropriate.
One patient received more than 10 years of chemotherapy after being misdiagnosed with a grade-4 glioblastoma, later revealed to be a grade-1 pilocytic astrocytoma, a low-grade tumor with potentially normal life expectancy requiring no chemotherapy. Another patient experienced more than 100 treatment cycles over a decade, enduring significant adverse effects including severe shingles requiring hospitalization and persistent nausea and vomiting. Patients reported being told that discontinuing treatment would result in death, despite stable imaging results.
The trust leadership issued an apology acknowledging the failures and their impact on patients and families. The report recommends that all living patients who received more than 12 cycles of temozolomide undergo independent case review. Legal representatives for over 40 affected patients are requesting a formal independent public inquiry into the matter.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI